PCMA Statement on the Pre-Approval Information Exchange Act

(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott today issued the following statement on H.R. 7008, the Pre-approval Information Exchange (PIE) Act:

“The introduction of the PIE Act is an important step forward in establishing a value-based health care system. We applaud Rep. Brett Guthrie (R-KY) for his longtime focus on increasing access to affordable prescription drugs for patients.

Allowing health plans and pharmacy benefit managers, PBMs, to access clinical and economic information about new drugs prior to the Food and Drug Administration’s approval will enable plans and PBMs to assess their efficacy and value compared to competing products, make more informed coverage decisions about them, more effectively estimate their impact on health care costs, and, most importantly, help patients get timely access. This policy is a central element of PCMA’s own Critical Path Forward for addressing prescription drug costs.

We look forward to working with Rep. Guthrie, the Energy and Commerce Committee, and Congress to advance the legislation.”


PCMA is the national association representing America’s pharmacy benefit managers (PBMs).  PBMs administer prescription drug plans for more than 266 million Americans who have health insurance from a variety of sponsors including:  commercial health plans, self-insured employer plans, union plans, Medicare Part D plans, the Federal Employees Health Benefits Program (FEHBP), state government employee plans, Medicaid plans, and others.